TapImmune, Inc. announced they will be featured in upcoming Daily Newsletters, Daily Blogs, and Message Boards. QualityStocks has over 750,000 subscribers to The Daily Stock Newsletter, which is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters and puts it all into one Free Daily Newsletter Report.
TapImmune, Inc. is focused on developing innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine, moves characteristic markers called antigens to the surfaces of cells. Without TAP, there is a large reduction in presentation of cancer markers, making it difficult for the immune system to spot rogue and cancerous cells, allowing them to grow undetected.
The company’s vaccine has demonstrated its effectiveness in restoring TAP which in-turn restores and augments the characteristic marker (antigen) and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works to enhance targeted vaccines against infectious diseases. For example, including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1,000 times.
Denis Corin, President of TapImmune, stated, “TapImmune has a unique and solid business foundation, and appreciates the opportunity to sponsor the QualityStocks Newsletter and Blogs. QualityStocks is providing a much needed service in the micro-cap and small-cap markets.”
About QualityStocks:
QualityStocks’ Small Cap Stock Newsletter is a free service that collects data from hundreds of Small-Cap online Investment Newsletters into one free Daily Newsletter Report.
Sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
The Quality Stocks Daily Stock Report http://video.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment